) for treatment discontinuation was 0.740 (95% CI: 0.385–1.423; P =.367). The pooled RR of all-grade side effects were as follows: diarrhea, 1.955 (95% CI: 1.304–2.933; P =.001); nausea, 1.038 (95% CI: 0.702–1.534; P =.852); vomiting, 1.048 (95% CI: 0
Search Results
CLO19-025: Treatment Discontinuation Due to Adverse Events and the Risk of Gastrointestinal Toxicities in Patients With Hematologic Malignancies Treated With Ibrutinib
Meily Arevalo, Myo H. Zaw, Anita Sultan, Sriman Swarup, Nay N. Yee, Wai L. Thein, Myet M. Zin, Nusrat Jahan, and Kyaw Z. Thein
Antiemetic Studies on the NK1 Receptor Antagonist Aprepitant
John P. Stoutenburg and Harry Raftopoulos
comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting . Eur J Cancer 1997 ; 33 : 66 – 74 . 2 Grunberg SM Hansen M Deuson R : Incidence and impact of nausea/vomiting with
Edmonton Symptom Assessment Scale and Clinical Characteristics Associated With Cannabinoid Use in Oncology Supportive Care Outpatients
Young D. Chang, Jae-Woo Jung, Ritika Oberoi-Jassal, Jongphil Kim, Sahana Rajasekhara, Meghan Haas, Joshua Smith, Vijay Desai, Kristine A. Donovan, and Diane Portman
, including chronic pain, spasticity, seizures, anorexia, nausea, and glaucoma. 2 – 4 In addition, marijuana has been highlighted as a potential immune-modulating or anticancer agent. 5 Given the symptom burden reported by patients in the oncology outpatient
Ten-Year Trends in Antiemetic Prescribing in Patients Receiving Highly Emetogenic Chemotherapy
Ciara C. O'Sullivan, Holly K. Van Houten, Lindsey R. Sangaralingham, Alexis D. Leal, Shivani Shinde, Hongfang Liu, David Ettinger, Charles L. Loprinzi, and Kathryn J. Ruddy
Chemotherapy-induced nausea and vomiting (CINV) is common during cancer treatment due to a complex multifactorial process involving several different pathways and transmitters. Highly emetogenic chemotherapy (HEC) regimens are associated with >90
What the HEC? Clinician Adherence to Evidence-Based Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy
Eric J. Roeland, Kathryn J. Ruddy, Thomas W. LeBlanc, Ryan D. Nipp, Gary Binder, Silvia Sebastiani, Ravi Potluri, Luke Schmerold, Eros Papademetriou, Lee Schwartzberg, and Rudolph M. Navari
Background Despite the availability of evidence-based guidelines for the prevention of chemotherapy-induced nausea and vomiting (CINV), adherence to these guidelines remains suboptimal. In addition to the impact on quality of life (QoL), poorly
Complications of Radioactive Iodine Treatment of Thyroid Carcinoma
Stephanie L. Lee
-term alterations in taste have been reported. Gastrointestinal Complications Nausea is the most common gastrointestinal symptom of RAI therapy but is rarely accompanied by emesis. 5 Studies have shown that 50% to 67% of patients complain of nausea
QIM19-130: Quality Improvement Project to Standardize a Prehabilitation Pathway for Patients With Esophageal Cancer Receiving Neoadjuvant Chemoradiation
Ashley E. Glode, S. Lindsey Davis, Supriya K. Jain, Megan D. Marsh, Lisa J. Wingrove, Tracey E. Schefter, Karyn Goodman, Lindel C.K. Dewberry, Martin D. McCarter, Laura Melton, Michelle Bunch, William T. Purcell, and Stephen Leong
treatments, with an average relative dose intensity of 111.4% for carboplatin and 112.9% for paclitaxel. In the pre-STRENGTH group, one patient did not complete their planned radiation dose due to nausea, vomiting, and dehydration. All patients in the
Adherence to the World Cancer Research Fund/American Institute for Cancer Research Guideline Is Associated With Better Health-Related Quality of Life Among Chinese Patients With Breast Cancer
Yuan-Yuan Lei, Suzanne C. Ho, Ashley Cheng, Carol Kwok, Chi-Kiu Iris Lee, Ka Li Cheung, Roselle Lee, Herbert H.F. Loong, Yi-Qian He, and Winnie Yeo
-specific HRQoL issues relevant to a broad spectrum of patients with cancer. 30 The QLQ-C30 included a global health and QoL domain, 5 functional domains (physical, role, emotional, cognitive, and social), 3 symptom domains (fatigue, nausea and vomiting, and pain
Antiemesis
Fox Chase Cancer Center
Chemotherapy-induced nausea and vomiting (emesis) can significantly affect a patient's quality of life, leading to poor adherence with further chemotherapy treatment. In addition, nausea and vomiting can result in other serious complications and deterioration of the patient's status. These guidelines explore the prevention, treatment, and management of various types of emesis experienced by cancer patients, such as breakthrough, radiation-induced, and anticipatory.
For the most recent version of the guidelines, please visit NCCN.org
CLO19-035: Safety Profile and Adverse Events of Sunitinib as a First-Line Treatment for Advanced/Metastatic Clear-Cell Renal Cell Carcinoma: Pooled Analysis of Randomized Controlled Trials
Tarek Haykal, Babikir Kheiri, Varun Samji, Yazan Zayed, Ragheed Al-Dulaimi, Inderdeep Gakhal, Areeg Bala, Jason Sotzen, Ahmed Abdalla, and Ghassan Bachuwa
Foundation, Vienna, Austria). Results: We included 8 RCTs, with a total of 4,106 patients. The mean age was 62, with 66.44% males. Any grade AEs were reported in 72% of patients with the following frequencies: fatigue, 44%; diarrhea, 38%; nausea, 31%; hand
